Connect Biopharma (CNTB) to Release Earnings on Friday

Key Points

• Connect Biopharma (CNTB) is set to announce its H1 2025 earnings on Friday, September 5th, with analysts predicting a loss of ($0.22) per share.
• Shares of Connect Biopharma opened at $1.76 and the company has a current ratio of 7.24 and a debt-to-equity ratio of 0.01.
• Analysts have varied opinions on the stock, with HC Wainwright maintaining a "buy" rating and a target price of $7.00, while others have upgraded it to a "strong-buy".

Connect Biopharma (NASDAQ:CNTB - Get Free Report) is expected to be issuing its H1 2025 results before the market opens on Friday, September 5th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter. Parties are encouraged to explore the company's upcoming H1 2025 earningoverview page for the latest details on the call scheduled for Wednesday, August 13, 2025 at 9:00 AM ET.

Connect Biopharma Trading Up 17.0%

CNTB traded up $0.30 on Friday, hitting $2.06. 194,143 shares of the stock traded hands, compared to its average volume of 133,508. Connect Biopharma has a 52 week low of $0.51 and a 52 week high of $2.86. The company has a current ratio of 7.24, a quick ratio of 7.24 and a debt-to-equity ratio of 0.01. The business has a fifty day moving average price of $1.70 and a two-hundred day moving average price of $1.11.

Institutional Investors Weigh In On Connect Biopharma

An institutional investor recently bought a new position in Connect Biopharma stock. XTX Topco Ltd acquired a new stake in Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 28,862 shares of the company's stock, valued at approximately $29,000. XTX Topco Ltd owned 0.05% of Connect Biopharma at the end of the most recent quarter. Institutional investors own 58.72% of the company's stock.

Wall Street Analysts Forecast Growth

CNTB has been the topic of several research reports. Wall Street Zen upgraded Connect Biopharma to a "hold" rating in a research note on Friday, August 22nd. HC Wainwright restated a "buy" rating and set a $7.00 price target on shares of Connect Biopharma in a research note on Wednesday, August 13th. Finally, Northland Capmk upgraded Connect Biopharma to a "strong-buy" rating in a research note on Tuesday, July 22nd. One analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the stock. According to MarketBeat.com, Connect Biopharma has an average rating of "Strong Buy" and an average price target of $7.00.

Connect Biopharma Company Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.